Preclinical Study Data on Astragaloside IV for Diabetic Kidney Disease

501.8 MB of experimental data investigates the renoprotective mechanism of Astragaloside IV in diabetic kidney disease. The dataset includes results from a 12-week mouse model study and in vitro podocyte experiments, uploaded by Guo Yaxiong in April 2026. It contains molecular, histological, and biochemical measurements related to the PHD2/HIF-1α signaling axis.

Use Cases

• Analyze correlations between treatment groups (AS-IV, LW6, DMOG) and molecular markers like GPX4, SLC7A11, NLRP3, and IL-1β levels.
• Train models to predict histological pathology scores from biochemical measurements such as iron accumulation and lipid peroxidation data.
• Validate network pharmacology predictions by examining the in vivo and in vitro binding stability data for AS-IV with PHD2 and HIF-1α targets.

Strengths

• Dataset size of 501.8 MB suggests a medium-scale collection of experimental results and images.
• Experimental design includes both in vivo (mouse model over 12 weeks) and in vitro (podocyte cultures) validation.

Limitations

• Sample size for the in vivo mouse model is not specified, which is critical for assessing statistical power.
• The dataset appears focused on a single compound's mechanism, limiting generalizability to other therapeutic approaches.

Provenance

Source

Figshare, uploaded by author Guo Yaxiong.

Collection Method

Data generated from preclinical laboratory experiments, including animal models and cell culture studies.

Time Range

Covers the experimental period, likely a 12-week intervention as described.

Freshness

Data was last updated in April 2026, indicating recent publication.